The trial currently has almost 10,000 patients enrolled and is expected to assess a composite MACE endpoint consisting of cardiovascular (CV) death, non-fatal myocardial infarction, or non-fatal stroke in patients with T2D as is expected to readout in July 2024 (NCT03574597)
First, it identifies pre-existing deficiencies that should be corrected before adding the metabolic stress of rapid weight loss
[20] [21] Seek urgent medical advice if you are already taking a GLP-1 medication and experience: Severe, persistent abdominal pain (possible pancreatitis) A new lump in your neck or changes in your voice Symptoms of severe hypoglycaemia (if taking other diabetes medications) Signs of thyroid dysfunction despite stable levothyroxine therapy Persistent vomiting leading to dehydration or inability to take oral medications Severe right upper abdominal pain, fever or jaundice (possible gallbladder disease) Open communication with your healthcare team ensures that treatment decisions are individualised, evidence-based, and aligned with your health priorities
When dose adjustments occur without monitoring, uncertainty increases and potential risks may go unnoticed
The slow approach is much easier for the drain to handle without flooding
Our specialists carefully evaluate each patient to ensure that Ozempic is a safe and effective option for their weight management goals
